Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-10

FDA Approved: NORTREL 21 DAY — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

The FDA approved Teva's supplemental application for Nortrel 21 Day, a generic combination oral contraceptive containing norethindrone and ethinyl estradiol.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NORTREL 21 DAY (NORETHINDRONE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for NORTREL 21 DAY (NORETHINDRONE AND ETHINYL ESTRADIOL)